Details

Autor(en) / Beteiligte

• Fernandez, Zoraida
• de Arruda Rodrigues, Rudielle
• Torres, Jaire Marinho
• Marcon, Gláucia Elisete Barbosa
• de Castro Ferreira, Eduardo
• de Souza, Vanessa Felipe
• Sarti, Elaine Fernandes Baez
• Bertolli, Guilherme Ferminao
• Araujo, Daniel
• Demarchi, Luiz Henrique Ferraz
• Lichs, Gislene
• Zardin, Marina Umaki
• Gonçalves, Crhistinne Cavalheiro Maymone
• Cuenca, Valter
• Favacho, Alexsandra
• Guilhermino, Jislaine
• dos Santos, Lenita Ramires
• de Araujo, Flábio Ribeiro
• Silva, Marcio Roberto

Titel

Development and validity assessment of ELISA test with recombinant chimeric protein of SARS-CoV-2

Ist Teil von

• Journal of immunological methods, 2023-08, Vol.519, p.113489-113489, Article 113489

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Serological tests developed for COVID-19 diagnostic are based on antibodies specific for SARS-CoV-2 antigens. Most of the antigens consist of a fragment or a whole amino acid sequence of the nucleocapsid or spike proteins. We evaluated a chimeric recombinant protein as an antigen in an ELISA test, using the most conserved and hydrophilic portions of the S1-subunit of the S and Nucleocapsid (N) proteins. These proteins, individually, indicated a suitable sensitivity of 93.6 and 100% and a specificity of 94.5 and 91.3%, respectively. However, our study with the chimera containing S1 and N proteins of SARS-CoV-2 suggested that the recombinant protein could better balance both the sensitivity (95.7%) and the specificity (95.5%) of the serological assay when comparing with the ELISA test using the antigens N and S1, individually. Accordingly, the chimera showed a high area under the ROC curve of 0.98 (CI 95% 0.958–1). Thus, our chimeric approach could be used to assess the natural exposure against SARS-CoV-2 virus over time, however, other tests will be necessary to better understand the behaviour of the chimera in samples from people with different vaccination doses and/or infected with different variants of the virus.